Tracking Mosaico, mRNA, and Broadly Neutralizing Antibody Vaccines
Updated July 2026. After 40+ years of research and over $100 billion invested, an effective HIV vaccine remains elusive. HIV's rapid mutation rate, integration into host DNA, and ability to establish latent reservoirs present unique challenges. As of 2026, no HIV vaccine candidate is in active Phase 3 development. All prior Phase 3 efficacy trials — RV144, HVTN 702 (Uhambo), HVTN 705/706 "Imbokodo" and Mosaico, and PrEPVacc — either failed to meet endpoints or were discontinued at interim analysis. Current efforts have shifted to earlier-phase work: mRNA HIV vaccines (Moderna/IAVI, applying COVID-19 vaccine technology; noted early safety signals include skin reactions in some trials), germline-targeting immunogens designed to prime rare B cell precursors of broadly neutralizing antibodies (bNAbs), and therapeutic vaccines aimed at HIV remission. A new Phase 1 trial, IAVI G004, is planned to launch in 2026 to test a booster designed to further strengthen antibody responses toward broadly protective bNAbs.